Mental Health Symptoms and Disease Activity Moved in Step in Axial Spondyloarthritis
In axial spondyloarthritis, anxiety, depression, and inflammatory disease burden did not split into separate clinical tracks. Across a large international cohort, latent class analysis and trajectory modelling failed to identify the kind of discordance investigators set out to find; instead, mental health symptoms and disease activity were closely aligned both at baseline and after treatment change.
That pattern matters at the bedside. It suggests the emotional and inflammatory components of the disease are often experienced together rather than as independent problems requiring entirely separate explanatory models.
The analysis drew on participants from the ASAS Health Index International Validation Study, using baseline data from 1,292 individuals and a treatment-change subgroup of 206 patients followed for 6 months. Baseline profiles were built from the Hospital Anxiety and Depression Scale subscores and the ASDAS, all standardized before modelling. In the longitudinal subset, the investigators looked for divergent trajectories after treatment change, with the hope of finding patients whose disease activity improved while mental health symptoms remained high, or the reverse.
Baseline Profiles Showed Concordance Rather Than Separation
Three groups emerged from the baseline latent class analysis, and each showed concordant HADS and ASDAS patterns. The groups differed mainly by overall severity, not by a split between physical and psychological burden. Patients in the highest symptom group had more peripheral joint involvement and higher CRP levels, while the remaining baseline characteristics were broadly similar across groups.
This is clinically intuitive. Inflammatory load can drive pain, stiffness, sleep disruption, fatigue, and the persistent sense of bodily threat that amplifies anxiety and low mood. Once those pathways are active at the same time, mental health scores and disease activity scores are likely to rise together rather than diverge cleanly. In practice, that means a patient with high anxiety or depression scores should not automatically be assumed to have a purely independent psychiatric syndrome detached from inflammatory activity; the disease itself may be contributing to both domains.
The high-activity, high-symptom group also carried a stronger inflammatory signal. Elevated CRP alongside peripheral joint involvement fits a phenotype with more systemic disease expression, and that may help explain why symptom burden clustered together in this subgroup.
Treatment Change Produced Parallel Shifts in Symptoms and Disease Activity
The 6-month trajectory analysis in 206 patients again found alignment, not discordance. Four groups were identified. More than half of patients, 54%, entered the study with comparatively low baseline values. Another 33% occupied a medium-burden group. Among the higher-burden patients, 7% showed marked improvement over time, with HADS-depression changing by 11 points, HADS-anxiety by 9 points, and ASDAS by 2.8. A smaller 6% subgroup improved less in disease activity, with an ASDAS change of 1.4 and only minimal anxiety improvement of 0.6.
The numbers are important because they show the mental health signal did not drift away from the inflammatory signal during the treatment window. Improvement in disease activity usually eased anxiety and depressive symptoms at the same time, suggesting shared downstream effects from pain relief, better sleep, restored function, and reduced uncertainty about flares. When treatment dampens inflammatory activity, the brain is no longer forced to process constant nociceptive input and symptom vigilance, and psychological distress may ease in parallel.
A smaller subset improved incompletely. Even there, the data did not reveal a clean psychological-inflammation split. Instead, limited ASDAS improvement tended to coexist with only small changes in anxiety, reinforcing the notion that the two measures are intertwined during active disease management.
Why the Expected Discordance May Not Have Appeared
The study was designed around a plausible clinical hypothesis: some patients might report high anxiety or depression despite modest inflammatory activity, while others might have active disease with little mental health impact. That pattern would have suggested two largely separate axes of illness. The findings did not support that model.
Several mechanisms can explain why the two domains stayed aligned. Active inflammation in axSpA can intensify pain and stiffness, disrupt sleep, and limit mobility, all of which erode mood and coping. Psychological distress, in turn, can magnify symptom perception, reduce physical activity, and make disease feel more severe than objective markers alone would suggest. The relationship may therefore be bidirectional, with each domain feeding the other rather than moving independently.
The practical implication is straightforward: when disease activity falls, mental health symptoms often fall with it. That does not eliminate the need to screen for anxiety and depression, but it does argue against assuming that mood symptoms in axSpA are always separable from inflammatory control.
What This Means for Routine Rheumatology Care
For clinicians, the most useful message is not that mental health symptoms should be ignored. It is the opposite. Anxiety and depression remain central patient-reported outcomes in axSpA, and this analysis suggests they should be interpreted in parallel with inflammatory disease measures instead of in isolation.
A patient presenting with severe symptom burden may improve on both fronts after effective treatment begins, and that possibility can shape counseling from the first visit. Patients with high mental health symptom burden may benefit from knowing that those symptoms often lessen when inflammatory disease comes under control. At the same time, the subset with incomplete improvement will still need careful follow-up, because residual pain, sleep disturbance, functional limitation, or persistent mood symptoms can continue to impair quality of life even when the inflammatory score has moved downward.
The study also carries a signal for treatment evaluation. If disease activity and mental health scores change together, both domains may be useful in judging response, particularly in patients whose baseline burden is high. A narrow focus on joint counts, CRP, or ASDAS alone can miss the full patient experience, while a narrow focus on mood alone can miss the inflammatory driver beneath it.
Study Constraints Leave Some Questions Open
The analysis was robust in scope, but it still reflects a selected cohort from the ASAS Health Index International Validation Study, and the longitudinal subgroup was much smaller than the baseline population. Only patients requiring treatment change were included in the trajectory analysis, which means the 6-month findings may not represent every patient with axSpA. The modelling also used standardized scores, which helps comparison but cannot fully replace the nuance of a clinician-patient conversation about pain, fatigue, sleep, and function.
Even with those limitations, the central result is hard to ignore: the anticipated split between inflammatory activity and mental health did not appear. In this cohort, the two moved together at baseline and after treatment change, pointing to a clinically intertwined disease burden rather than two separate stories unfolding at once.